trending Market Intelligence /marketintelligence/en/news-insights/trending/dodp6_kke7k8uoynedwoca2 content esgSubNav
In This List

Clovis Oncology seeks expanded indication for ovarian cancer drug in EU

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clovis Oncology seeks expanded indication for ovarian cancer drug in EU

Clovis Oncology Inc. submitted an application with the European Medicines Agency, seeking approval to expand the indication of its drug Rubraca.

Specifically, the company wants its drug to be used as a so-called maintenance therapy to improve the effectiveness of chemotherapy in adult patients with certain types of ovarian cancer.

The company expects an opinion from the regulator by the end of 2018.

The medicine is approved in Europe as a treatment for BRCA mutated epithelial ovarian, fallopian tube or primary peritoneal cancer patients who have been treated at least twice with chemotherapy and are unable to tolerate it any further.

It is also approved in the U.S. to keep ovarian cancer from recurring in certain patients after chemotherapy.